Wilfred van Zuilen Promoted to Group
President, EMEA
Mark Bezjak Promoted to President of the
Americas
Chief Science, Technology and Innovation
Officer Nitin Goyal, M.D. Appointed to Executive Leadership
Team
WARSAW,
Ind., Sept. 5, 2023
/PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a
global medical technology leader, today announced key updates to
the Company's Executive Leadership Team. Wilfred van Zuilen
has been promoted to Group President, EMEA; Mark Bezjak was promoted to President of the
Americas; and Chief Science, Technology and Innovation
Officer Nitin Goyal, M.D. has been appointed to the Executive
Leadership Team, all reporting directly to President and Chief
Executive Officer Ivan Tornos.
"The expansion of Zimmer Biomet's Executive Leadership Team
coincides with our renewed focus on commercial execution and
innovation to drive the Company forward," said Mr. Tornos. "These
appointments demonstrate the continued evolution of our business
strategy as we remain focused on developing our team to drive value
for patients, customers and all stakeholders."
Wilfred Van Zuilen Promotion to Group President,
EMEA
Mr. van Zuilen joined Zimmer Biomet in June 2021 as President, EMEA. He will continue to
be responsible for the sales, marketing and distribution of
products in the EMEA region, and in his expanded role, he will
also lead select global R&D projects.
Prior to joining Zimmer Biomet, Mr. van Zuilen served as
Regional Vice President, North Western Europe (United Kingdom, Ireland, Nordics and Benelux) at Medtronic.
Prior to that, he led Medtronic's Restorative Therapies Group of
businesses for EMEA and has also held regional leadership positions
with Covidien, Novartis and Edwards Lifesciences. Mr. van Zuilen
holds a bachelor's degree in Business Economics from Erasmus University in Rotterdam.
Mark Bezjak Promotion to President of the Americas
Mark Bezjak joined Zimmer Biomet
in April of 2008 as Director of Corporate Sales and has held roles
of increasing importance with the Company, most recently serving as
the President of North America,
since 2021. In his expanded role, he will add oversight of
Latin America to his current
responsibilities for all commercial, downstream marketing and
distribution activities in North
America.
Prior to his work at Zimmer Biomet, Mr. Bezjak held
multiple roles with Teleflex Medical and Michelin Tire Company. He
holds a Bachelor of Science degree in Marketing from Virginia Tech and an MBA in Strategic Leadership
from the University of Richmond.
Nitin Goyal, M.D. Appointment
to Executive Leadership Team
Dr. Goyal joined Zimmer Biomet in June 2021 in the newly created role of Chief
Science, Technology and Innovation Officer. With his appointment,
he will continue to have oversight of all global innovation,
medical education, clinical affairs, and reimbursement strategy,
now reporting to the President and CEO.
Dr. Goyal is a practicing adult hip and knee reconstruction
surgeon. Prior to joining Zimmer Biomet, he also served as Chief
Medical Officer and Senior Vice President of Innovation and Digital
Care Delivery at Rally Health, part of the Optum business of
UnitedHealth Group. Dr. Goyal is the Founder and CEO of Pulse
Platform as well as Surgical Creations, leading both companies from
inception to acquisition. He received his Bachelor's degree from
Penn State University, his Medical
degree from the Jefferson Medical College and completed his
residency in Orthopedic Surgery and fellowship in Adult
Reconstruction at the Rothman Institute and Thomas Jefferson University Hospital in
Philadelphia, Pennsylvania.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader
with a comprehensive portfolio designed to maximize mobility and
improve health. We seamlessly transform the patient experience
through our innovative products and suite of integrated digital and
robotic technologies that leverage data, data analytics and
artificial intelligence.
With 90+ years of trusted leadership and proven expertise,
Zimmer Biomet is positioned to deliver the highest quality
solutions to patients and providers. Our legacy continues to come
to life today through our progressive culture of evolution and
innovation.
For more information about our product portfolio, our operations
in 25+ countries and sales in 100+ countries or about joining our
team, visit www.zimmerbiomet.com or follow Zimmer Biomet
on Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of forward-looking terms
such as "may," "will," "expects," "believes," "aims,"
"anticipates," "plans," "looking forward to," "estimates,"
"projects," "assumes," "guides," "targets," "forecasts,"
"continue," "seeks" or the negatives of such terms or other
variations on such terms or comparable terminology. Forward-looking
statements include, but are not limited to, statements concerning
the Company's expectations, plans, intentions, strategies,
prospects, business plans, product and service offerings, new
product launches, potential clinical successes, and other
statements that are not historical facts. Such statements are based
upon the current beliefs and expectations of management and are
subject to significant risks and uncertainties that could cause
actual outcomes and results to differ materially. Some of these
risks and uncertainties can be found in Zimmer Biomet's Annual
Report on Form 10-K for the year ended December 31, 2022 and subsequent periodic reports
filed with the Securities and Exchange Commission (SEC). Copies of
these filings are available online at
www.sec.gov, www.zimmerbiomet.com or on
request from the Company. These factors should not be construed as
exhaustive and should be read in conjunction with the other
cautionary statements that are included in the Company's filings
with the SEC. Such forward-looking statements speak only as of the
date made, and the Company disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. Readers of
this press release are cautioned not to place undue reliance on
these forward-looking statements, since there can be no assurance
that these forward-looking statements will prove to be accurate.
This cautionary statement is applicable to all forward-looking
statements contained in this press release.
Media
|
|
Investors
|
Meredith
Weissman
|
|
Keri Mattox
|
(703)
346-3127
|
|
(215)
275-2431
|
meredith.weissman@zimmerbiomet.com
|
|
keri.mattox@zimmerbiomet.com
|
|
|
|
Heather
Zoumas-Lubeski
(445)
248-0577
heather.zoumaslubeski@zimmerbiomet.com
|
|
Zach Weiner
(908)
591-6955
zach.weiner@zimmerbiomet.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-announces-key-updates-to-companys-executive-leadership-team-301917918.html
SOURCE Zimmer Biomet Holdings, Inc.